Literature DB >> 20638987

Estrogen and glucocorticoid regulate osteoblast differentiation through the interaction of bone morphogenetic protein-2 and tumor necrosis factor-alpha in C2C12 cells.

Yoshinori Matsumoto1, Fumio Otsuka, Mariko Takano, Tomoyuki Mukai, Ryutaro Yamanaka, Masaya Takeda, Tomoko Miyoshi, Kenichi Inagaki, Ken-ei Sada, Hirofumi Makino.   

Abstract

Imbalanced functions between osteoclasts and osteoblasts are involved in inflammatory bone damage. The clinical effectiveness of blocking TNF-alpha in treatment of active rheumatoid arthritis established the significance of TNF-alpha in the pathogenesis. In the present study, we investigated the cellular mechanism by which estrogen and glucocorticoid interact in osteoblastic differentiation regulated by BMP and TNF-alpha using mouse myoblastic C2C12 cells. The expression of estrogen receptors, (ER)alpha and ERbeta, and glucocorticoid receptor (GCR) was significantly increased by BMP-2 treatment regardless of the presence of estradiol and dexamethasone. Estradiol, but not dexamethasone, enhanced BMP-induced Runx2 and osteocalcin expression in C2C12 cells. In addition, TNF-alpha suppressed BMP-2-induced Runx2 and osteocalcin expression, and estradiol and dexamethasone reversed the TNF-alpha effects on BMP-2-induced Runx2 expression. Dexamethasone also abolished osteocalcin expression induced by BMP-2. Interestingly, BMP-2-induced Smad1/5/8 phosphorylation and Id-1 promoter activity were enhanced by estradiol pretreatment. On the other hand, dexamethasone suppressed BMP-2-induced Smad1/5/8 activation. TNF-alpha-induced SAPK/JNK activity was suppressed by estradiol, while NFkappaB phosphorylation was inhibited by dexamethasone. Of note, the inhibitory effects of TNF- on BMP-2-induced Runx2 and osteocalcin expression were reversed by SAPK/JNK inhibition regardless of the presence of estradiol. The estradiol effects that enhance BMP-2-induced Runx2 and osteocalcin mRNA expression were restored by antagonizing ER, and moreover, membrane-impermeable estradiol-BSA failed to enhance the BMP-2-induced osteoblastic differentiation. Thus, estrogen and glucocorticoid are functionally involved in the process of osteoblast differentiation regulated by BMPs and TNF-alpha. BMP-2 increases the sensitivities of ERs and GCR, whereas estrogen and glucocorticoid differentially regulate BMP-Smad and TNF-alpha signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638987     DOI: 10.1016/j.mce.2010.05.004

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  18 in total

1.  Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells.

Authors:  H Huang; N Zhao; X Xu; Y Xu; S Li; J Zhang; P Yang
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

2.  Cyclic AMP Response Element-binding Protein H (CREBH) Mediates the Inhibitory Actions of Tumor Necrosis Factor α in Osteoblast Differentiation by Stimulating Smad1 Degradation.

Authors:  Won-Gu Jang; Byung-Chul Jeong; Eun-Jung Kim; Hyuck Choi; Sin-Hye Oh; Don-Kyu Kim; Seung-Hoi Koo; Hueng-Sik Choi; Jeong-Tae Koh
Journal:  J Biol Chem       Date:  2015-04-14       Impact factor: 5.157

3.  LPS-stimulated inflammatory environment inhibits BMP-2-induced osteoblastic differentiation through crosstalk between TLR4/MyD88/NF-κB and BMP/Smad signaling.

Authors:  Ru-Lin Huang; Yuwen Yuan; Gang-Ming Zou; Guangwang Liu; Jun Tu; Qingfeng Li
Journal:  Stem Cells Dev       Date:  2013-11-07       Impact factor: 3.272

4.  Activated NF-κB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling.

Authors:  Yu Tang; Hao Xie; Jinyun Chen; Linyu Geng; Haifeng Chen; Xia Li; Yayi Hou; Liwei Lu; Songtao Shi; Xiaofeng Zeng; Lingyun Sun
Journal:  Stem Cells Dev       Date:  2012-10-10       Impact factor: 3.272

5.  BMP-2/CPC scaffold with dexamethasone-loaded blood clot embedment accelerates clinical bone regeneration.

Authors:  Yutong Liu; Dan Lin; Bo Li; Hua Hong; Chuan Jiang; Yuan Yuan; Jinwu Wang; Ruyin Hu; Bo Li; Changsheng Liu
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

6.  BMPR2 expression is suppressed by signaling through the estrogen receptor.

Authors:  Eric D Austin; Rizwan Hamid; Anna R Hemnes; James E Loyd; Tom Blackwell; Chang Yu; John A Phillips Iii; Radhika Gaddipati; Santhi Gladson; Everett Gu; James West; Kirk B Lane
Journal:  Biol Sex Differ       Date:  2012-02-20       Impact factor: 5.027

7.  Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective.

Authors:  André Barkhordarian; Reem Ajaj; Manisha H Ramchandani; Gary Demerjian; Riana Cayabyab; Sohrab Danaie; Nora Ghodousi; Natasha Iyer; Nicole Mahanian; Linda Phi; Amy Giroux; Ercolano Manfrini; Negoita Neagos; Muniza Siddiqui; Olivia S Cajulis; Xenia M C Brant; Paul Shapshak; Francesco Chiappelli
Journal:  Patholog Res Int       Date:  2011-05-21

8.  Dexamethasone enhances osteogenic differentiation of bone marrow- and muscle-derived stromal cells and augments ectopic bone formation induced by bone morphogenetic protein-2.

Authors:  Masato Yuasa; Tsuyoshi Yamada; Takashi Taniyama; Tomokazu Masaoka; Wei Xuetao; Toshitaka Yoshii; Masaki Horie; Hiroaki Yasuda; Toshimasa Uemura; Atsushi Okawa; Shinichi Sotome
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

9.  BMPR1B up-regulation via a miRNA binding site variation defines endometriosis susceptibility and CA125 levels.

Authors:  Cherry Yin-Yi Chang; Yi Chen; Ming-Tsung Lai; Hui-Wen Chang; Jack Cheng; Carmen Chan; Chih-Mei Chen; Shan-Chih Lee; Ying-Ju Lin; Lei Wan; Pei-Wen Tsai; Su-Han Yang; Ching Chung; Jim Jinn-Chyuan Sheu; Fuu-Jen Tsai
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

10.  Cyclin G2 suppresses estrogen-mediated osteogenesis through inhibition of Wnt/β-catenin signaling.

Authors:  Jinlan Gao; Qi Liu; Xing Liu; Chunyan Ji; Shengqiang Qu; Shusen Wang; Yang Luo
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.